These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 5869967)

  • 1. [Studies on maple syrup disease in 2 families].
    Goedde HW; Richter E; Hüfner M; zur Mühlen A von
    Humangenetik; 1964; 1(2):163-9. PubMed ID: 5869967
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunosuppressive effects of organic acids accumulating in patients with maple syrup urine disease.
    Wajner M; Schlottfeldt JL; Ckless K; Wannmacher CM
    J Inherit Metab Dis; 1995; 18(2):165-8. PubMed ID: 7564237
    [No Abstract]   [Full Text] [Related]  

  • 3. Branched-chain alpha-keto acids isolated as oxime derivatives: relationship to the corresponding hydroxy acids and amino acids in maple syrup urine disease.
    Lancaster G; Mamer OA; Scriver CR
    Metabolism; 1974 Mar; 23(3):257-65. PubMed ID: 4813956
    [No Abstract]   [Full Text] [Related]  

  • 4. Myelin proteins: degradation in rat brain initiated by metabolites causative of maple syrup urine disease.
    Tribble D; Shapira R
    Biochem Biophys Res Commun; 1983 Jul; 114(2):440-6. PubMed ID: 6411085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Branched chain alpha-keto acid metabolism. I. Isolation, purification, and partial characterization of bovine liver alpha-ketoisocaproic:alpha-keto-beta-methylvaleric acid dehydrogenase.
    Connelly JL; Danner DJ; Bowden JA
    J Biol Chem; 1968 Mar; 243(6):1198-203. PubMed ID: 5689906
    [No Abstract]   [Full Text] [Related]  

  • 6. Chloride-dependent inhibition of vesicular glutamate uptake by alpha-keto acids accumulated in maple syrup urine disease.
    Reis M; Farage M; Wolosker H
    Biochim Biophys Acta; 2000 Jul; 1475(2):114-8. PubMed ID: 10832024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [HETEROZYGOTE TEST FOR MAPLE SYRUP URINE DISEASE. DETERMINATION OF THE ENZYMATIC ACTIVITY OF ALPHA-KETOISOCAPROIC ACID OXIDASE IN LEUKOCYTES].
    GOEDDE HW; RICHTER E; STAHLMANN C; SIXEL B
    Klin Wochenschr; 1963 Oct; 41():953-4. PubMed ID: 14092946
    [No Abstract]   [Full Text] [Related]  

  • 8. The inhibition of pyruvate decarboxylation in rat brain by -ketoisocaproic acid.
    Bowden JA; McArthur CL; Fried M
    Biochem Med; 1971 Apr; 5(2):101-8. PubMed ID: 5167175
    [No Abstract]   [Full Text] [Related]  

  • 9. Heterogeneity in maple syrup urine disease: aspects of cofactor requirement and complementation in cultured fibroblasts.
    Singh S; Willers I; Goedde HW
    Clin Genet; 1977 Apr; 11(4):277-84. PubMed ID: 192504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A case of maple syrup urine disease. Biochemical study].
    Lamedica GM; Fregonese B; Moroni G; Famularo L
    Minerva Pediatr; 1972 Dec; 24(43):2143-9. PubMed ID: 4652219
    [No Abstract]   [Full Text] [Related]  

  • 11. How to detect maple-syrup urine disease in newborn infants.
    Fogelson MH
    Clin Pediatr (Phila); 1970 Sep; 9(9):538. PubMed ID: 5465716
    [No Abstract]   [Full Text] [Related]  

  • 12. [CLINICAL, BIOCHEMICAL, AND NEUROPATHOLOGIC ASPECTS OF MAPLE SYRUP URINE DISEASE. A KETOACIDURIA OF THE OPEN CHAIN AMINOACIDS LEUCINE, ISOLEUCINE AND VALINE].
    SILBERMANSCHWARTZMAN J
    An Fac Med Lima; 1963 Sep; 46():339-65. PubMed ID: 14122039
    [No Abstract]   [Full Text] [Related]  

  • 13. Synaptic plasma membrane Na(+), K (+)-ATPase activity is significantly reduced by the alpha-keto acids accumulating in maple syrup urine disease in rat cerebral cortex.
    Wajner A; Bürger C; Dutra-Filho CS; Wajner M; de Souza Wyse AT; Wannmacher CM
    Metab Brain Dis; 2007 Mar; 22(1):77-88. PubMed ID: 17295076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidation of leucine, isoleucine and related ketoacids in developing rabbit brain.
    Swaiman KF; Milstein JM
    J Neurochem; 1965 Dec; 12(12):981-6. PubMed ID: 5892498
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of a heterozygote test for maple syrup urine disease in leucocytes and cultured fibroblasts.
    Langenbeck U; Rüdiger HW; Schulze-Schencking M; Keller W; Brackertz D; Goedde HW
    Humangenetik; 1971; 11(4):304-15. PubMed ID: 5550595
    [No Abstract]   [Full Text] [Related]  

  • 16. Prolongation of G1 and S phase in C-6 glioma cells treated with maple syrup urine disease metabolits. Morphologic and cell cycle studies.
    Liao CL; Herman MM; Bensch KG
    Lab Invest; 1978 Feb; 38(2):122-33. PubMed ID: 564423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A rapid method for assay of branched-chain keto acid decarboxylation in cultured cells and its application to prenatal diagnosis of maple syrup urine disease.
    Fensom AH; Benson PF; Baker JE
    Clin Chim Acta; 1978 Jul; 87(1):169-74. PubMed ID: 668138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The enzyme defect in maple syrup urine disease (branched chain ketoaciduria).
    Seegmiller JE; Westall RG
    J Ment Defic Res; 1967 Dec; 11(4):288-94. PubMed ID: 5582930
    [No Abstract]   [Full Text] [Related]  

  • 19. Maple syrup urine disease: alpha-ketoisocaproate decarboxylation activity in different types of cultured amniotic fluid cells.
    Wendel U; Gamm G; Claussen U
    Prenat Diagn; 1981 Oct; 1(4):235-40. PubMed ID: 7346826
    [No Abstract]   [Full Text] [Related]  

  • 20. Transaminations between amino acids and keto acids elevated in phenylketonuria and maple syrup urine disease.
    Lees GJ; Weiner N
    J Neurochem; 1973 Feb; 20(2):389-403. PubMed ID: 4698286
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.